MicroRNA-219 loaded chitosan nanoparticles for treatment of glioblastoma

被引:27
作者
Alswailem, Rawan [1 ,2 ]
Alqahtani, Fulwah Yahya [2 ]
Aleanizy, Fadilah Sfouq [2 ]
Alrfaei, Bahauddeen M. [3 ]
Badran, Mohammad [2 ]
Alqahtani, Qamraa Hamad [4 ]
Abdelhady, Hosam Gharib [5 ]
Alsarra, Ibrahim [2 ]
机构
[1] Saudi Food & Drug Author, Drug Sect, Riyadh, Saudi Arabia
[2] King Saud Univ, Coll Pharm, Dept Pharmaceut, Riyadh, Saudi Arabia
[3] King Saud Bin Abdulaziz Univ Hlth, King Abdullah Int Med Res Ctr, Dept Cellular Therapy & Canc Res, Riyadh, Saudi Arabia
[4] King Saud Univ, Coll Pharm, Dept Pharmacol & Toxicol, Riyadh, Saudi Arabia
[5] Sam Houston State Univ, Coll Osteopath Med, Conroe, TX USA
关键词
Glioblastoma; microRNA; Chitosan; Nanoparticles; gene delivery; microRNA-219; CELL-PENETRATING PEPTIDES; INTRACELLULAR TRAFFICKING; DELIVERY; CLASSIFICATION; THERAPY; RELEASE;
D O I
10.1080/21691401.2022.2092123
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Recent evidence has implicated microRNA-219 (miR-219) in regulation of gene contributed in glioblastoma (GBM) pathogenesis. This study aimed to prepare miR-219 in chitosan (CS) nanoparticles (NPs), characterize and investigate their efficacy on human GBM cell line (U87 MG). NPs were prepared using ionic gelation method. The influence of process parameters on physicochemical characteristics of NPs was investigated. Apoptotic effect of miR-219 was examined on U87 MG cells. Formulated NPs showed particle size of 109 +/- 2.18 nm, with poly dispersity index equal to 0.2 +/- 0.05, and zeta potential of +20.5 +/- 0.7 mV. Entrapment efficiency of miR-219 in loaded NP has reached 95%. The in vitro release study demonstrated sustained release pattern of miR-219 from CS-NPs. Gel retardation assay has confirmed the integrity of miR-219 after production process. The fabricated NPs reduced the survival of U87 MG cells to 78% after 24 h of post-transfection, and into 67.5% after 48 h. However, fibroblasts were not affected by the NPs, revealing their specificity for GBM cells. Given the tumour suppressing function of miR-219, and advantage of CS-NPs for gene delivery to the central nervous system, the presented NPs have a great potential for treatment of GBM.
引用
收藏
页码:198 / 207
页数:10
相关论文
共 65 条
[1]   Recent advances on chitosan-based micro- and nanoparticles in drug delivery [J].
Agnihotri, SA ;
Mallikarjuna, NN ;
Aminabhavi, TM .
JOURNAL OF CONTROLLED RELEASE, 2004, 100 (01) :5-28
[2]   The Spectrum of Vaccine Therapies for Patients With Glioblastoma Multiforme [J].
Aguilar, Laura K. ;
Arvizu, Mariel ;
Aguilar-Cordova, Estuardo ;
Chiocca, E. Antonio .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2012, 13 (04) :437-450
[3]   MicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review [J].
Ahir, Bhavesh K. ;
Ozer, Howard ;
Engelhard, Herbert H. ;
Lakka, Sajani S. .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 120 :22-33
[4]   OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs [J].
Anaya, Jordan .
PEERJ COMPUTER SCIENCE, 2016, 2016 (06)
[5]  
[Anonymous], 2014, MICRORNA TARGETED CA
[6]   MicroRNA in Glioblastoma: An Overview [J].
Banelli, Barbara ;
Forlani, Alessandra ;
Allemanni, Giorgio ;
Morabito, Anna ;
Pistillo, Maria Pia ;
Romani, Massimo .
INTERNATIONAL JOURNAL OF GENOMICS, 2017, 2017
[7]   Clinical Practice Guideline Series Update [J].
Blissitt, Patricia A. .
JOURNAL OF NEUROSCIENCE NURSING, 2014, 46 (06) :367-368
[8]   Chitosans for delivery of nucleic acids [J].
Buschmann, Michael D. ;
Merzouki, Abderrazzak ;
Lavertu, Marc ;
Thibault, Marc ;
Jean, Myriam ;
Darras, Vincent .
ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (09) :1234-1270
[9]  
Cai Xue, 2018, Oncotarget, V9, P9540, DOI 10.18632/oncotarget.23476
[10]   Recent Advances in Chitosan-Based Carriers for Gene Delivery [J].
Cao, Ye ;
Tan, Yang Fei ;
Wong, Yee Shan ;
Liew, Melvin Wen Jie ;
Venkatraman, Subbu .
MARINE DRUGS, 2019, 17 (06)